George Fennell Sells 9,986 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $457.35 on Thursday. The stock’s 50 day moving average is $429.67 and its two-hundred day moving average is $453.23. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The firm has a market capitalization of $37.45 billion, a PE ratio of 42.86, a P/E/G ratio of 3.47 and a beta of 1.37. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 0.28.

Analyst Ratings Changes

A number of brokerages have commented on IDXX. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Piper Sandler lifted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday. Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Finally, Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

Institutional Investors Weigh In On IDEXX Laboratories

Several institutional investors have recently made changes to their positions in IDXX. Livforsakringsbolaget Skandia Omsesidigt increased its stake in IDEXX Laboratories by 400.0% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 500 shares of the company’s stock valued at $253,000 after purchasing an additional 400 shares in the last quarter. Carnegie Investment Counsel purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $205,000. Procyon Advisors LLC grew its stake in IDEXX Laboratories by 2.2% during the third quarter. Procyon Advisors LLC now owns 1,544 shares of the company’s stock worth $780,000 after buying an additional 33 shares during the period. Creative Planning boosted its position in shares of IDEXX Laboratories by 2.6% in the third quarter. Creative Planning now owns 24,436 shares of the company’s stock worth $12,346,000 after buying an additional 614 shares during the period. Finally, RDA Financial Network grew its position in IDEXX Laboratories by 25.2% in the third quarter. RDA Financial Network now owns 1,771 shares of the company’s stock valued at $895,000 after acquiring an additional 357 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.